Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 102


Effective, broad spectrum control of virulent bacterial infections using cationic DNA liposome complexes combined with bacterial antigens.

Ireland R, Olivares-Zavaleta N, Warawa JM, Gherardini FC, Jarrett C, Hinnebusch BJ, Belisle JT, Fairman J, Bosio CM.

PLoS Pathog. 2010 May 27;6(5):e1000921. doi: 10.1371/journal.ppat.1000921.


Mucosal immunotherapy for protection from pneumonic infection with Francisella tularensis.

Troyer RM, Propst KL, Fairman J, Bosio CM, Dow SW.

Vaccine. 2009 Jul 16;27(33):4424-33. doi: 10.1016/j.vaccine.2009.05.041. Epub 2009 May 31.


Nasal Acai polysaccharides potentiate innate immunity to protect against pulmonary Francisella tularensis and Burkholderia pseudomallei Infections.

Skyberg JA, Rollins MF, Holderness JS, Marlenee NL, Schepetkin IA, Goodyear A, Dow SW, Jutila MA, Pascual DW.

PLoS Pathog. 2012;8(3):e1002587. doi: 10.1371/journal.ppat.1002587. Epub 2012 Mar 15.


Protection against pneumonic plague following oral immunization with a non-replicating vaccine.

Jones A, Bosio C, Duffy A, Goodyear A, Schriefer M, Dow S.

Vaccine. 2010 Aug 16;28(36):5924-9. doi: 10.1016/j.vaccine.2010.06.020. Epub 2010 Jun 19.


Kdo hydrolase is required for Francisella tularensis virulence and evasion of TLR2-mediated innate immunity.

Okan NA, Chalabaev S, Kim TH, Fink A, Ross RA, Kasper DL.

MBio. 2013 Feb 12;4(1):e00638-12. doi: 10.1128/mBio.00638-12.


EmrA1 membrane fusion protein of Francisella tularensis LVS is required for resistance to oxidative stress, intramacrophage survival and virulence in mice.

Ma Z, Banik S, Rane H, Mora VT, Rabadi SM, Doyle CR, Thanassi DG, Bakshi CS, Malik M.

Mol Microbiol. 2014 Mar;91(5):976-95. doi: 10.1111/mmi.12509. Epub 2014 Feb 8.


Protection from pneumonic infection with burkholderia species by inhalational immunotherapy.

Goodyear A, Kellihan L, Bielefeldt-Ohmann H, Troyer R, Propst K, Dow S.

Infect Immun. 2009 Apr;77(4):1579-88. doi: 10.1128/IAI.01384-08. Epub 2009 Jan 29.


Post-exposure immunization against Francisella tularensis membrane proteins augments protective efficacy of gentamicin in a mouse model of pneumonic tularemia.

Sutherland MD, Goodyear AW, Troyer RM, Chandler JC, Dow SW, Belisle JT.

Vaccine. 2012 Jul 13;30(33):4977-82. doi: 10.1016/j.vaccine.2012.05.037. Epub 2012 May 28.


Yopp-expressing variant ofY. pestis activates a potent innate immune response affording cross-protection against yersiniosis and tularemia.

Zauberman A, Flashner Y, Levy Y, Vagima Y, Tidhar A, Cohen O, Bar-Haim E, Gur D, Aftalion M, Halperin G, Shafferman A, Mamroud E.

PLoS One. 2013 Dec 16;8(12):e83560. doi: 10.1371/journal.pone.0083560. eCollection 2013.


Identification of circulating bacterial antigens by in vivo microbial antigen discovery.

Nuti DE, Crump RB, Dwi Handayani F, Chantratita N, Peacock SJ, Bowen R, Felgner PL, Davies DH, Wu T, Lyons CR, Brett PJ, Burtnick MN, Kozel TR, AuCoin DP.

MBio. 2011 Aug 16;2(4). pii: e00136-11. doi: 10.1128/mBio.00136-11. Print 2011.


Identification of a live attenuated vaccine candidate for tularemia prophylaxis.

Mahawar M, Rabadi SM, Banik S, Catlett SV, Metzger DW, Malik M, Bakshi CS.

PLoS One. 2013 Apr 17;8(4):e61539. doi: 10.1371/journal.pone.0061539. Print 2013.


Identification of Francisella tularensis outer membrane protein A (FopA) as a protective antigen for tularemia.

Hickey AJ, Hazlett KR, Kirimanjeswara GS, Metzger DW.

Vaccine. 2011 Sep 16;29(40):6941-7. doi: 10.1016/j.vaccine.2011.07.075. Epub 2011 Jul 29.


Identification of Francisella tularensis live vaccine strain CuZn superoxide dismutase as critical for resistance to extracellularly generated reactive oxygen species.

Melillo AA, Mahawar M, Sellati TJ, Malik M, Metzger DW, Melendez JA, Bakshi CS.

J Bacteriol. 2009 Oct;191(20):6447-56. doi: 10.1128/JB.00534-09. Epub 2009 Aug 14.


Low dose vaccination with attenuated Francisella tularensis strain SchuS4 mutants protects against tularemia independent of the route of vaccination.

Rockx-Brouwer D, Chong A, Wehrly TD, Child R, Crane DD, Celli J, Bosio CM.

PLoS One. 2012;7(5):e37752. doi: 10.1371/journal.pone.0037752. Epub 2012 May 25.


The Fischer 344 rat reflects human susceptibility to francisella pulmonary challenge and provides a new platform for virulence and protection studies.

Ray HJ, Chu P, Wu TH, Lyons CR, Murthy AK, Guentzel MN, Klose KE, Arulanandam BP.

PLoS One. 2010 Apr 1;5(4):e9952. doi: 10.1371/journal.pone.0009952.


Interleukin-17 protects against the Francisella tularensis live vaccine strain but not against a virulent F. tularensis type A strain.

Skyberg JA, Rollins MF, Samuel JW, Sutherland MD, Belisle JT, Pascual DW.

Infect Immun. 2013 Sep;81(9):3099-105. doi: 10.1128/IAI.00203-13. Epub 2013 Jun 17.


Francisella tularensis tmRNA system mutants are vulnerable to stress, avirulent in mice, and provide effective immune protection.

Svetlanov A, Puri N, Mena P, Koller A, Karzai AW.

Mol Microbiol. 2012 Jul;85(1):122-41. doi: 10.1111/j.1365-2958.2012.08093.x. Epub 2012 May 28.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk